Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

Other drug agents

Bio-reagents and biochemicals

MedKoo's

Anticancer molecular libraries

IGF-IR inhibitor library

(IGF-IR = insulin-like growth factor receptor-I receptor)

As insulin-like growth factor (IGF) signaling has been recognized to play an important role in human cancer, the IGF-I receptor (IGF-IR) is currently the focus of intensive research aimed at developing novel antitumor agents. The IGF system is frequently deregulated in cancer cells by the establishment of autocrine loops involving IGF-I or -II and/or IGF-IR over-expression. Moreover, epidemiological studies have suggested a link between elevated IGF levels and the development of major human malignancies, such as breast, colon, lung and prostate cancer. Experimental therapies aimed at inhibiting IGF signaling in human tumors involve various approaches, including neutralizing antibodies and pharmacological inhibitors of IGF-IR kinase activity. (source: Drug News Perspect. 2006 Jun;19(5):261-72.)

AG-1024 (IGF-IR inhibitor)
AQIP  (IGF-IR inhibitor)
BMS-317180 (IGF-IR inhibitor, growth hormone secretagogue)
BMS-536924 (IGF-IR inhibitor)
BMS-554417 (IGF-IR inhibitor)
BVP-51004（Cyclolignan PPP） (IGF-IR inhibitor)
Genistein (IGF-IR inhibitor)
INSM-18  (IGF-IR inhibitor)

Linsitinib (OSI-906) (IGF-IR inhibitor)
NDGA（Nordihydro-guaiaretic acid) (IGF-IR inhibitor)
NVP-ADW742 (IGF-IR inhibitor)
NVP-AEW541 (IGF-IR inhibitor)
NVP-TAE226 (IGF-IR inhibitor)
Picropodophyllin (IGF-IR inhibitor)
Silymarin  (IGF-IR inhibitor)
SOM230 (Pasireotide) IGF-IR inhibitor)
XL-228 (IGF-IR inhibitor)

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)